Adial Pharmaceuticals, Inc. has announced strategic manufacturing agreements with Thermo Fisher Scientific and Cambrex to support the production of its lead investigational therapy, AD04. The drug is being developed for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. Thermo Fisher has been
Cambrex, a global CDMO, announced its partnership with Lilly Catalyze360-ExploR&D, the innovation arm of Eli Lilly and Company, to provide development services for Lilly’s biotech collaborators. The collaboration will accelerate early-stage drug development through Cambrex’s expertise in drug substance, drug
Cambrex, a global contract development and manufacturing organisation (CDMO), has announced the opening of a new cGMP stability storage facility in Durham, North Carolina. The facility, operated by its subsidiary Q1 Scientific, expands the company’s capability to provide temperature-controlled storage
Cambrex, a contract development and manufacturing organisation, is set to expand its stability storage business, Q1 Scientific, by opening a new facility in Durham, North Carolina. This facility, scheduled to be operational by the end of 2024, will feature advanced
Cambrex, a contract development and manufacturing organisation (CDMO), is nearing the completion of its ambitious 5-year, $100-million-dollar investment strategy with the completion of the project expected by the end of 2024. The investment strategy, which was originally planned to span
Cambrex is a Pharmaceutical company, Manufacturer/Innovator, Contract Service, CMO/CDMO, Biopharmaceutical company company operating in the pharmaceutical industry. Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance, drug product, and analytical services across the entire
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
